Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 9, 2017, Pages 2065-2071

  Solanki, Bhagirath B ^a   Juergens, Christine ^b   Chopada, Manojkumar B ^c   Supe, Pravin ^d   Sundaraiyer, Vani ^e   Le Dren Narayanin, Natacha ^f   Cutler, Mark W ^b   Gruber, William C ^b   Scott, Daniel A ^b   Schmoele Thoma, Beate ^b  

^a BJ Medical College and Civil Hospital   (India)

^b PFIZER INC   (United States)

^c Chopda Medicare and Research Centre Pvt Ltd   (India)

^d Supe Heart and Diabetes Hospital and Research Centre   (India)

^e SYNEOS HEALTH   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

adults; immunogenicity; India; safety; thirteen valent pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; VACCINE;

ADULT; APPETITE; ARTHRALGIA; ARTICLE; ASTHMA; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COUGHING; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOGENICITY; INDIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMOCOCCAL INFECTION; PUBLIC HEALTH; REVACCINATION; SINGLE DRUG DOSE; VIRUS INFECTION; AGED; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; SECONDARY IMMUNIZATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINE IMMUNOGENICITY;

AGED; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INDIA; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 85029953868     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1331796     Document Type: Article

References (28)

1. World Health Organization. Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec 2012; 87:129-44; PMID:24340399
2. World Health Organization. 23-valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec 2008; 83:373-84; PMID:18927997
3. Suzman R, Beard JR, Boerma T, Chatterji S. Health in an ageing world–what do we know? Lancet 2015; 385:484-6; PMID:25468156; https://doi.org/10.1016/S0140-6736(14)61597-X
4. Thomas K, Mukkai Kesavan L, Veeraraghavan B, Jasmine S, Jude J, Shubankar M, Kulkarni P, Steinhoff M, Ibis Study Group IndiaCLEN Network. Invasive pneumococcal disease associated with high case fatality in India. J Clin Epidemiol 2013; 66:36-43; PMID:23177893; https://doi.org/10.1016/j.jclinepi.2012.04.006
5. Central Statistics Office. Situation analysis of the elderly in India. Ministry of Statistics & Programme Implementation, Government of India. Available at: http://mospi.nic.in/sites/default/files/publication_reports/elderly_in_india.pdf. Accessed December1, 2016
6. Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, Samaria JK, Gaur SN, Jindal SK, Pneumonia Guidelines Working Group. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India 2012; 29:S27-62; PMID:23019384; https://doi.org/10.4103/0970-2113.99248
7. Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis 2013; 17:e364-373; https://doi.org/10.1016/j.ijid.2013.01.004
8. Kanungo R. Knowledge of serotype prevalence & burden of invasive pneumococcal disease: a prerequisite to vaccine introduction in the country. Indian J Med Res 2015; 142:241-4; PMID:26458339; https://doi.org/10.4103/0971-5916.166528
9. Prevention of pneumonia through vaccination. J Assoc Physicians India 2013; 61:38-40; PMID:24779157
10. Expert Group of the Association of Physicians of India on Adult Immunization in India. The Association of Physicians of India evidence-based clinical practice guidelines on adult immunization. J Assoc Physicians India 2009; 57:345-56; PMID:19702046
11. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - a systematic review and meta-analysis. PLoS ONE 2016; 11:e0146338; PMID:26761816; https://doi.org/10.1371/journal.pone.0146338
12. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8; PMID:23000122; https://doi.org/10.1016/j.vaccine.2012.09.019
13. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-06; PMID:20814406
14. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet 1999; 353:1216-21; PMID:10217081; https://doi.org/10.1016/S0140-6736(98)07228-6
15. Molander V, Elisson C, Balaji V, Backhaus E, John J, Vargheese R, Jayaraman R, Andersson R. Invasive pneumococcal infections in Vellore, India: clinical characteristics and distribution of serotypes. BMC Infect Dis 2013; 13:532; PMID:24206667; https://doi.org/10.1186/1471-2334-13-532
16. Shariff M, Choudhary J, Zahoor S, Deb M. Characterization of Streptococcus pneumoniae isolates from India with special reference to their sequence types. J Infect Dev Ctries 2013; 7:101-9; PMID:23416655; https://doi.org/10.3855/jidc.2553
17. Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention Working Group. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009; 27:7282-91; PMID:19393708; https://doi.org/10.1016/j.vaccine.2009.04.046
18. Ada G. Vaccines and vaccination. N Engl J Med 2001; 345:1042-53; PMID:11586958; https://doi.org/10.1056/NEJMra011223
19. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408-16; PMID:22457293; https://doi.org/10.1093/infdis/jis212
20. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; https://doi.org/10.1056/NEJMoa1408544
21. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822-5; PMID:25233284
22. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015; 64:944-47; PMID:26334788; https://doi.org/10.15585/mmwr.mm6434a4
23. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; https://doi.org/10.1016/j.vaccine.2013.04.085
24. Tinoco JC, Juergens C, Ruiz Palacios GM, Vazquez-Narvaez J, Enkerlin-Pauwells HL, Sundaraiyer V, Pathirana S, Kalinina E, Gruber WC, Scott DA, et al. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico. Clin Vaccine Immunol 2015; 22:185-92; PMID:25499011; https://doi.org/10.1128/CVI.00711-14
25. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008; 26:3551-55; PMID:18524433; https://doi.org/10.1016/j.vaccine.2008.04.054
26. Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, Belanger T, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥ 50 years: an open-label trial. Hum Vaccin Immunother 2014; 10:1850-58; PMID:25424792; https://doi.org/10.4161/hv.28633
27. Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines. Pediatr Infect Dis J 2013; 32:266-73; PMID:23011012
28. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine 2014; 32:2364-74; https://doi.org/10.1016/j.vaccine.2014.02.002